The suite of cell therapy components includes NK- and T-cell specific CAR and switch receptors, which are intended to improve the safety and efficacy of cell therapies by allowing for more precise control over activation and targeting.
The custom CARs are designed to enhance a cell therapy’s proliferation and cytotoxicity to generate a more robust and durable response against target cells.
The switch receptors use specific ligands to enable CAR-T or CAR-NK cell therapies to respond to environmental signals, including inhibitory ones.
Modulus’ tech will be integrated into Ginkgo's cell therapy service platform, which allows partners to sample CAR domains with various functional roles and structural positions, sourced from diverse immune cell types. Tuesday’s deal with Modulus follows a series of collaborations to bulk out the synthetic biology company’s genetic medicines offerings. Earlier this year, Ginkgo gained several key technologies, including ProteoNic’s vector production platform; Form Bio’s in silico suite for construct characterisation, simulation, and design optimization; and Patch Biosciences’s AI toolkit for DNA sequence design for more effective, specific, and durable genetic medicines.